NORTHWELL HEALTH
- Country
- πΊπΈUnited States
- Ownership
- -
- Established
- 1997-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.northwell.edu/
Clinical Trials
448
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (328 trials with phase data)β’ Click on a phase to view related trials
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
- Conditions
- Colorectal Cancer Metastatic
- First Posted Date
- 2025-09-26
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 10
- Registration Number
- NCT07193862
- Locations
- πΊπΈ
RJ Zuckerberg, Lake Success, New York, United States
Emotional Urinary Tract Infection
- Conditions
- Urinary Tract Infection(UTI)Recurrent Urinary Tract Infections
- First Posted Date
- 2025-09-24
- Last Posted Date
- 2025-09-24
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 170
- Registration Number
- NCT07191041
- Locations
- πΊπΈ
NHPP Urology, Syosset, New York, United States
Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)
- Conditions
- Diamond Blackfan Anemia
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 10
- Registration Number
- NCT07186179
- Locations
- πΊπΈ
Cohen Children's Medical Center, New Hyde Park, New York, United States
INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases
- Conditions
- Colorectal Cancer Metastatic
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 10
- Registration Number
- NCT07172282
- Locations
- πΊπΈ
RJ Zuckerberg, Lake Success, New York, United States
Monthly Alternating NALIRIFOX and GnP in the First-Line Setting
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- Drug: NALIRIFOXDrug: Gemcitabine plus nab-Paclitaxel (GnP)
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 41
- Registration Number
- NCT07163273
- Locations
- πΊπΈ
Zuckerberg Cancer Center, New Hyde Park, New York, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 90
- Next
News
Evernorth Health Services Makes $3.5 Billion Investment in Shields Health Solutions to Expand Specialty Pharmacy Network
Evernorth Health Services, a subsidiary of The Cigna Group, announced a $3.5 billion preferred stock investment in Shields Health Solutions to strengthen specialty pharmacy management capabilities.
TAS-102 Shows Promise in Clearing Circulating Tumor DNA in Colorectal Cancer Patients with Minimal Residual Disease
TAS-102 demonstrated significant ctDNA clearance rates of 47% at 3 months and 36% at 6 months in colorectal cancer patients with minimal residual disease, compared to only 6.7% in the synthetic control cohort.
EBUS-Guided Lung Biopsies Demonstrate Superior Safety Profile for Comprehensive Biomarker Testing
A multidisciplinary expert panel from leading pulmonology organizations concluded that endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) provides safer tissue sampling than percutaneous approaches while maintaining adequate sample quality for biomarker testing.
FDA Clears Advanced UroNav System for Precision Focal Therapy in Prostate Cancer
The FDA has granted 510(k) clearance to an updated version of the Philips UroNav System, featuring advanced annotation workflow for enhanced precision in minimally invasive prostate cancer focal therapy procedures.
SurgiVance Secures $2.2M NIH Grant to Advance Direct-to-Digital Pathology Platform
SurgiVance Inc. received a $2,245,000 National Cancer Institute Small Business Innovation Research Direct-to-Phase II grant to commercialize its "pathology lab-in-a-box" technology.
COVID-19 Boosters Reduce Hospitalization Risk by 29% in Cancer Patients, Large Multi-Center Study Shows
A large retrospective study of over 161,000 cancer patients across four major U.S. health systems found that COVID-19 booster vaccines reduced hospitalizations and ICU admissions by 29%.
Implanted Vagus Nerve Stimulation Device Shows Promise for Treatment-Resistant Rheumatoid Arthritis
A computer chip implanted in the neck that stimulates the vagus nerve demonstrated significant symptom relief in a rheumatoid arthritis patient who had failed eight previous medications.
Innocan Pharma Advances Liposomal CBD Platform for Chronic Pain as Peer-Reviewed Study Highlights Non-Opioid Alternative
A peer-reviewed narrative review published in Cureus journal highlights the therapeutic potential of long-acting synthetic cannabidiol (CBD) for chronic pain management as a non-opioid alternative.
Experts Emphasize Need for Patient-Centered Value in Healthcare Research
Healthcare experts at the 2025 Methods Summit stressed that research must align with patient preferences beyond traditional clinical metrics to deliver true value.
New Research Reveals How Vagus Nerve Encodes Immune Signals During Inflammation
Feinstein Institutes researchers have discovered how the vagus nerve detects and communicates specific inflammatory signals to the brain, revealing a complex encoding system for immune information.